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ABSTRACT
Objectives: To investigate the association between
factors influencing prostate-specific antigen (PSA)
testing prevalence including prostate cancer risk
factors (age, ethnicity, obesity) and non-risk factors
(social deprivation and comorbidity).
Setting: A cross-sectional database of 136 inner
London general practices from 1 August 2009 to 31
July 2014.
Participants: Men aged ≥40 years without prostate
cancer were included (n=150 481).
Primary outcome: Logistic regression analyses were
used to estimate the association between PSA testing
and age, ethnicity, social deprivation, body mass index
(BMI) and comorbidity while adjusting for age, benign
prostatic hypertrophy, prostatitis and tamsulosin or
finasteride use.
Results: PSA testing prevalence was 8.2% (2013–
2014), and the mean age was 54 years (SD 11). PSA
testing was positively associated with age (OR 70–
74 years compared to 40–44 years: 7.34 (95% CI 6.82
to 7.90)), ethnicity (black) (OR compared to white:
1.78 (95% CI 1.71 to 1.85)), increasing BMI and
cardiovascular comorbidity. Testing was negatively
associated with Chinese ethnicity and with increasing
social deprivation.
Conclusions: PSA testing among black patients was
higher compared to that among white patients, which
differs from lower testing rates seen in previous
studies. PSA testing was positively associated with
prostate cancer risk factors and non-risk factors.
Association with non-risk factors may increase the risk
of unnecessary invasive diagnostic procedures.
BACKGROUND
Prostate cancer is the commonest cancer in
men in the UK with 41 736 new cases in
2011 and the second commonest cause of
cancer death in men in the UK with 10 837
deaths in 2012.1 2 Known prostate cancer risk
factors are increasing age, family history,
ethnicity (black men) and obesity.2 3
Prostate cancer is rare in the under 50s, but
the incidence rises rapidly with those aged
75–79 years at ﬁve times higher risk com-
pared to 55–59 years old.2 Black men are
reported to have a three times greater risk
of developing prostate cancer compared to
white men.4 5 In the UK, the reported
age-adjusted incidence rates for African
Caribbeans is 647 per 100 000 compared to
213 for Europeans and 199 for South
Asians.5 A raised body mass index (BMI) has
also been implicated as possible prostate
cancer risk factor with some studies report-
ing a twofold increased risk in obese men.3 6
Currently, no prostate cancer screening
programme exists in the UK and a policy for
screening men aged 50–74 years every
4 years would cost an additional £800 million
per annum.7 Current UK recommendations
are that asymptomatic men aged over 50 who
wish to have a prostate-speciﬁc antigen
(PSA) test may do so after careful consider-
ation of the implications, but general practi-
tioners (GPs) are not encouraged to
proactively raise the issue of PSA testing.8
The prostate cancer risk management
Strengths and limitations of this study
▪ This study features a large, inclusive general
practice-registered population with representation
from a wide range of ethnicity groups.
▪ Use of computerised general practice coded and
prostate-specific antigen (PSA) data minimised
information entry errors.
▪ This study explores the important associations
between PSA testing and factors that may influ-
ence testing threshold including prostate cancer
risk factors, social deprivation and comorbidity.
▪ This study shows an increased testing rate
among black men which marks a positive
change in testing behaviour compared to prior
studies.
▪ Data on the reasoning for PSA testing were not
available in this study.
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programme, introduced in 2002, provides patients and
clinicians with balanced information on the advantages
and disadvantages of PSA testing and is used to help
concerned men make informed decisions regarding PSA
testing.8 There still remains a high degree of variability
in PSA testing, with a recent qualitative study showing
that GPs have varied beliefs about the risks of prostate
cancer over or under diagnosis which inﬂuences the
likelihood of testing.9 Therefore, PSA testing may be
inﬂuenced by other factors, such as comorbidity, that
are not directly associated with prostate cancer but
which may be associated with the GPs’ beliefs about the
impact of invasive testing or diagnosis of prostate cancer.
PSA screening remains controversial and conﬂicting
evidence exists as to the beneﬁts of screening on pros-
tate cancer mortality. While the European Randomised
Study of Screening for Prostate Cancer showed a
reduced mortality rate in patients undergoing PSA
screening,10 the US Prostate, Lung, Colorectal and
Ovarian (PLCO) trial showed no statistically signiﬁcant
difference in mortality rates.11 However, the PLCO study
had a higher contamination rate in the control group
with 45% of patients having had an opportunistic PSA
test in the 3 years prior to study randomisation.11 The
PSA test has poor speciﬁcity in regards to prostate
cancer diagnosis with up to 76% of men having a falsely
raised PSA level.7 Moreover, the large number of men
screened for prostate cancer have local or indolent
disease and up to 84% of men diagnosed with prostate
cancer survive 10 years or more;2 10 12 13 hence, the risk
of unnecessary invasive diagnostic or treatment strategies
with associated harmful side effects such as sexual dys-
function and incontinence is ever present.10 12 13
Conversely, prostate cancer remains the second com-
monest cause of cancer death in men in the UK and
earlier diagnosis and treatment, especially in some
patients with aggressive disease could reduce morbidity
and mortality.12 Moreover, active surveillance is used as
an initial management option for some patients with low
risk prostate cancer reducing the negative risks of inva-
sive treatment.12
The PSA testing rate per year in the UK is estimated
to be ∼6% in men aged 45–89 years and remained
unchanged between 2004 and 2011.14 15 PSA testing has
previously been reported to vary with increasing age,
ethnicity (decreased in black patients), geographical
location, social deprivation, decision tool use and test
indication.14–16 However, previous studies have relied
upon self-reported data16 or have had a restrictive age
inclusion criteria.14 15 Moreover, previous studies have
not fully explored the inﬂuence of ethnicity in detail14
nor investigated the possible inﬂuence of comorbidity
on PSA testing. The aim of this study is to investigate the
association between PSA testing prevalence and factors
that may inﬂuence testing including prostate cancer risk
factors (age, ethnicity and obesity) and non-risk factors
of social deprivation and comorbidity.
METHODS
Study data and setting
Data for the study were taken from the inner east
London boroughs of Newham, City and Hackney and
Tower Hamlets and covered >95% of the general
practice-registered population. Routine clinical data were
entered on practice computers using EMIS Web software.
Anonymised Read coded clinical and prescription data
recorded over a 5-year period were extracted from 136
participating practices in July 2014. Data were managed
according to the UK National Health Service information
governance requirements and ethical approval was not
required for this anonymised observational study.
Participant selection
We included all male patients aged ≥40 years on 31 July
2014. Patients with a recorded history of prostate cancer
ever were excluded as PSA testing in this setting would
be for monitoring purposes and not for the detection of
incident cases. Data from 150 481 patients were included
in the cross-sectional study as shown in ﬁgure 1.
PSA measurement
The latest PSA measurement per patient recorded
during the 5-year study period was used to categorise
patients into tested and untested PSA groups; free and
total PSA measurements were included. Patients with a
PSA measurement were categorised into 0–0.99,
1–3.99, 4–9.99 and ≥10 ng/mL groups. The PSA
testing prevalence was calculated as the percentage of
tested study participants over the 5-year and 1-year
(August 2013–2014) period. Data on the reasoning for
PSA testing were not available in this study.
Figure 1 PSA testing study selection flow chart. PSA,
prostate-specific antigen.
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Study cofactors
Sociodemographics
Data on patient age, ethnicity and individual-level
Townsend score (calculated using patient postcodes) as
a measure of deprivation were extracted. The Townsend
score is a census-based measure of deprivation and is
widely used to assess deprivation in the UK.17 Patients
were categorised into 5-year age groups and were placed
into approximate deprivation quintiles based on the
relative Townsend scores; 272 (0.18%) patients did not
have a Townsend score on record. Ethnicity was self-
reported by patients during practice visits and recorded
using 2001 UK census ethnicity codes. For the purposes
of this study, ethnic groups were grouped into white
(British, Irish, other white), black (African, Caribbean,
other black), mixed black, South Asian (Indian,
Pakistani, Bangladeshi, other Asian), Chinese, mixed
Asian, other mixed and other ethnicity. Those without a
recorded ethnicity were categorised as ‘not deﬁned’ and
included in the analysis. There were 13 149 patients
(8.7%) without a recorded ethnicity.
Body mass index
Data on the BMI (kg/m2) were extracted for the study
period with the latest BMI used to categorise patients.
Patients were categorised into normal weight (18.5–
24.9), underweight (<18.5), overweight (25–29.9), obese
class I (30–34.9), class II (35–39.9) and class III (≥40)
groups. There were 11 462 (7.6%) patients without a
recorded BMI.
Comorbidity
Comorbidities included in this study were placed into
four disease clusters.
1. The cardiovascular cluster, which included ischaemic
heart disease, peripheral vascular disease, heart
failure and atrial ﬁbrillation grouped together as car-
diovascular disease (CVD). Hypertension (HTN),
type I and II diabetes mellitus (DM), chronic kidney
disease (stages 3–5) and stroke/transient ischaemic
attack were also individually included in the cardio-
vascular cluster.
2. The respiratory cluster, which included asthma and
chronic obstructive pulmonary disease.
3. The mental health cluster, which included dementia
and serious mental illness (SMI). SMI group
included schizophrenia, bipolar disorder, mania and
psychosis.
4. Other cancer (excluding prostate cancer).
The selected comorbidities were chosen as they were
all Quality Outcome Framework (HSCIC, 2014)-related
domains, hence were well recorded and represented
prevalent, clinical conditions that GPs may take into con-
sideration when deciding upon the appropriateness of
PSA testing. Presence of the select comorbidities was
identiﬁed from the data using unique clinical codes
(Read codes) used in UK general practice data coding.
Adjusted covariates
Presence of benign prostatic hypertrophy (BPH) or pros-
tatitis was deﬁned as a diagnosis existing at any point
throughout the patient records. Data on tamsulosin or
ﬁnasteride use, used for the treatment of symptomatic
BPH, were also extracted and were deﬁned as the issue of
a prescription at any point during the 5-year study
period. BPH and prostatitis symptoms and presentation
overlap with those of prostate cancer, which may prompt
PSA testing, hence their inclusion. Similarly, ﬁnasteride
and tamsulosin, used for the treatment of BPH, inﬂuence
PSA levels or disease symptomology, hence may inﬂuence
the decision to undertake PSA testing.
Statistical methods
Normally distributed continuous variables were ana-
lysed as means and SDs, and dichotomous variables
were analysed as counts and percentages. Parametric
tests for signiﬁcant differences were determined using
unpaired t–test or χ2 test as appropriate.
Logistic regression analyses, with 95% CIs, were used to
assess the association between the odds of PSA testing and
age, ethnicity, deprivation quintile, BMI and comorbidity
(the comorbidity cluster and individual comorbidities
were tested). The 40–44 years, white, least deprived quin-
tile, normal weight, absence of the comorbidity cluster or
individual comorbidity acted as the reference for the afore-
mentioned cofactors. Two adjusted models were derived
per cofactor analyses: (1) an age-adjusted model and (2)
an age-adjusted and covariate-adjusted (BPH, prostatitis,
tamsulosin or ﬁnasteride use) model. All statistical analyses
were carried out on SPSS, V.20.0 (IBM, USA).
RESULTS
Characteristics of PSA tested and untested patients
The prevalence of PSA testing over the previous 5 years
was 17.6% (n=26 427, practice IQR 12.2–20.3%) for male
patients aged ≥40 years. The 1 year PSA testing prevalence
(1 August 2013–31 July 2014) was 8.2% (n=11 065, practice
IQR 4.8–9.7%). The mean age of included patients was
53.6 years (SD 11.4). Over 66% were classiﬁed as over-
weight or obese and a signiﬁcant proportion had HTN
(25.5%), DM (15.6%) or CVD (9.1%). There were signiﬁ-
cant differences in the age, ethnicity, social deprivation,
BMI, comorbidity and covariate status between PSA tested
and untested patients (p<0.001, table 1).
PSA testing prevalence, level and age
As shown in ﬁgure 2A, the PSA testing prevalence
increased signiﬁcantly with age from 5.1% at age 40–44
years to 39.7% at age 70–74 years (p<0.001). However,
the greatest proportion of PSA tests performed occurred
in patients aged 55–59 years (16.1%) with just 7% of all
PSA tests performed in patients aged 70–74 years.
The PSA level rose signiﬁcantly with age, with 0.8% of
patients aged 40–44 years having a PSA level of 4 ng/mL
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or greater, rising to 17.5% by age 70–74 years and 36.9%
by age 90–94 years (ﬁgure 2B). The median (IQR) PSA
values were 0.68 ng/mL (0.45–1.00) for 40–49 years,
0.81 ng/mL (0.50–1.40) for 50–59 years, 1.20 ng/mL
(0.65–2.30) for 60–69 years, 1.63 ng/mL (0.80–3.30) for
70–79 years, 2.08 ng/mL (0.93–4.28) for 80–89 years and
2.90 ng/mL (1.25–6.31) for ≥90 years.
Association between PSA testing and age, ethnicity,
social deprivation, BMI and comorbidity
PSA testing was positively associated with age. The
adjusted OR of PSA testing in the 70–74 years age group
was 7.34 (95% CI 6.82 to 7.90), compared to those base-
line 40–44 years age group (table 2). Moreover, the odds
of PSA testing increased in each age cohort peaking at
Table 1 Baseline characteristics of PSA tested and untested patients
Baseline characteristics
All
(n=150 481)
PSA untested
(n=124 054)
PSA tested
(n=26 427) p Value*
Prostate cancer risk factors
Age, mean (SD) 53.6 (11.4) 52.1 (10.7) 60.8 (11.9) <0.001
Ethnicity, % (N)
White 40.9 (61 621) 41.0 (50 897) 40.6 (10 724) <0.001
Black 17.2 (25 956) 16.0 (19 835) 23.2 (6121)
South Asian† 26.1 (39 341) 26.5 (32 858) 24.5 (6483)
Chinese 0.9 (1363) 1.0 (1200) 0.6 (163)
Mixed black 1.5 (2299) 1.3 (1647) 2.5 (652)
Mixed Asian† 0.2 (235) 0.2 (195) 0.2 (40)
Other mixed 0.4 (608) 0.4 (535) 0.3 (73)
Other ethnicity 3.9 (5909) 3.9 (4857) 4.0 (1052)
Not specified 8.7 (13 149) 9.7 (12 030) 4.2 (1119)
BMI class‡, % (N)
Normal weight 31.6 (47 619) 35.4 (40 140) 29.1 (7479) <0.001
Underweight 1.0 (1558) 1.2 (1321) 0.9 (237)
Overweight 39.1 (58 787) 42.0 (47 614) 43.5 (11 173)
Obese class I 15.3 (22 985) 15.9 (17 993) 19.4 (4992)
Obese class II 4.0 (6026) 4.1 (4653) 5.3 (1373)
Obese class III 1.4 (2044) 1.4 (1586) 1.8 (458)
Non-risk factors
Deprivation§, % (N)
Least deprived 21.8 (32 780) 21.5 (26 646) 23.2 (6134) <0.001
Q2 16.6 (25 022) 16.6 (20 519) 17.1 (4503)
Q3 17.1 (25 802) 17.2 (21 253) 17.2 (4549)
Q4 19.0 (28 637) 19.1 (23 654) 18.9 (4983)
Most deprived 25.2 (37 968) 25.6 (31 748) 23.6 (6220)
Comorbidity, % (N)
HTN 25.5 (38 399) 21.6 (26 814) 43.8 (11 585) <0.001
CVD 9.1 (13 635) 7.4 (9220) 16.7 (4415) <0.001
DM 15.6 (23 421) 13.8 (17 100) 23.9 (6321) <0.001
CKD stages 3–5 4.1 (6098) 3.2 (3918) 8.2 (2180) <0.001
Stroke 2.4 (3583) 2.0 (2458) 4.3 (1125) <0.001
Asthma 8.5 (12 792) 8.1 (10 012) 10.5 (2780) <0.001
COPD 3.5 (5206) 2.9 (3550) 6.3 (1656) <0.001
Dementia 0.6 (920) 0.5 (600) 1.2 (320) <0.001
SMI 2.5 (3699) 2.5 (3094) 2.3 (605) 0.510
Cancer¶ 1.8 (2719) 1.5 (1898) 3.1 (821) <0.001
Covariates
BPH, % (N) 3.5 (5271) 1.4 (1787) 13.2 (3484) <0.001
Prostatitis, % (N) 1.6 (2405) 0.9 (1113) 4.9 (1292) <0.001
Tamsulosin use, % (N) 7.2 (10 825) 3.2 (4021) 25.7 (6804) <0.001
Finasteride use, % (N) 2.4 (3610) 1.1 (1419) 8.3 (2191) <0.001
Bold typeface indicates significance at p≤0.05.
*χ2 between tested and untested groups.
†Indian, Pakistani, Bangladeshi or other Asian.
‡11 462 BMI values missing.
§Townsend score quintiles (272 scores missing).
¶Excludes benign or malignant prostate cancer.
BPH, benign prostate hypertrophy; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular
disease; DM, diabetes mellitus; HTN, hypertension; PSA, prostate-specific antigen; SMI, significant mental illness.
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70–74 years and decreasing thereafter up to the
≥95 years age group.
Compared to white patients, black (adjusted OR 1.78
(95% CI 1.71 to 1.85)), mixed black and to lesser
degree South Asian patients were signiﬁcantly more
likely to undergo PSA testing. This remained true for
black and mixed black patients after further adjust-
ment for included comorbidity clusters (data not
shown), but the OR for South Asians become non-
signiﬁcant. Conversely, Chinese patients were signiﬁ-
cantly less likely to undergo PSA testing than white
patients (table 2); there was minimal change in the
OR after adjusting for included comorbidities (data
not shown).
Increasing social deprivation was inversely associated
with the odds of PSA testing (table 2).
Compared to patients of a normal BMI, obese patients
were signiﬁcantly more likely to undergo PSA testing
(adjusted OR 1.29 (95% CI 1.24 to 1.35)). The likeli-
hood of PSA testing increased with each BMI class above
normal weight and decreased in underweight patients
(table 2).
PSA testing was signiﬁcantly associated with cardiovascu-
lar comorbidity, especially with HTN. Dementia but not
SMI showed an inverse association with PSA testing. There
was a weak association between PSA testing and respiratory
disease with no signiﬁcant difference in testing in patients
with a diagnosis of other cancer (table 2).
DISCUSSION
Summary
PSA testing prevalence was positively associated with
increasing age, black, mixed black and South Asian eth-
nicity, increasing BMI and cardiovascular comorbidity. In
contrast, PSA testing was inversely associated with
Chinese ethnicity and greater social deprivation.
Prevalence of PSA testing
Based on our ﬁndings, the 1-year PSA testing prevalence
in inner east London (8.2%) was higher than the 6.2%
reported in previous studies by Melia et al14 and
Williams et al.15 However, both studies excluded
older patients with an inclusion age criteria of 45–84
Figure 2 (A, B) PSA testing
prevalence, level and age. PSA,
prostate-specific antigen.
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Table 2 Association between PSA testing and age, ethnicity, social deprivation, BMI and comorbidity
Cofactor Description
PSA study group (N=150 481)
Unadjusted
OR (95% CI)
Age-adjusted
OR (95% CI)*
Age-adjusted and
covariate-adjusted
OR (95% CI)†
Prostate cancer risk factors
Age 40–44 years (n=37 668) 1.00 (Reference) NA 1.00 (Reference)
45–49 years (n=30 792) 2.04 (1.92 to 2.17) NA 2.00 (1.88 to 2.12)
50–54 years (n=24 982) 3.66 (3.45 to 3.87) NA 3.44 (3.25 to 3.65)
55–59 years (n=18 658) 5.47 (5.17 to 5.79) NA 4.81 (4.54 to 5.10)
60–64 years (n=12 814) 7.37 (6.94 to 7.82) NA 5.91 (5.56 to 6.29)
65–69 years (n=8839) 9.21 (8.64 to 9.81) NA 6.71 (6.28 to 7.17)
70–74 years (n=6105) 11.31 (10.55 to 12.11) NA 7.34 (6.82 to 7.90)
75–79 years (n=5152) 12.14 (11.29 to 13.05) NA 6.86 (6.35 to 7.42)
80–84 years (n=3320) 11.64 (10.71 to 12.65) NA 6.02 (5.49 to 6.60)
85–89 years (n=1527) 11.24 (10.04 to 12.59) NA 5.41 (4.77 to 6.14)
90–94 years (n=522) 9.63 (7.99 to 11.61) NA 4.35 (3.54 to 5.35)
≥95 years (n=102) 6.98 (4.51 to 10.81) NA 3.25 (2.02 to 5.24)
Ethnicity White (n=61 621) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Black (n=25 956) 1.47 (1.41 to 1.52) 1.74 (1.68 to 1.81) 1.78 (1.71 to 1.85)
South Asian‡
(n=39 341)
0.94 (0.91 to 0.97) 1.13 (1.09 to 1.17) 1.08 (1.04 to 1.12)
Chinese (n=1363) 0.65 (0.55 to 0.76) 0.66 (0.56 to 0.78) 0.67 (0.56 to 0.80)
Mixed black (n=2299) 1.88 (1.71 to 2.06) 2.23 (2.02 to 2.46) 2.25 (2.03 to 2.50)
Mixed Asian‡ (n=235) 0.97 (0.69 to 1.37) 1.23 (0.86 to 1.76) 1.21 (0.83 to 1.76)
Other mixed (n=608) 0.65 (0.51 to 0.83) 1.03 (0.80 to 1.32) 1.00 (0.77 to 1.30)
Other ethnicity (n=5909) 1.03 (0.96 to 1.10) 1.19 (1.11 to 1.29) 1.10 (1.02 to 1.19)
Not defined (n=13 149) 0.44 (0.41 to 0.48) 0.57 (0.53 to 0.61) 0.60 (0.56 to 0.65)
BMI§ Normal weight
(n=47 619)
1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Underweight (n=1558) 0.96 (0.84 to 1.11) 0.79 (0.68 to 0.92) 0.82 (0.70 to 0.95)
Overweight (n=58 787) 1.26 (1.22 to 1.30) 1.19 (1.15 to 1.23) 1.18 (1.14 to 1.22)
Obese class I
(n=22 985)
1.49 (1.43 to 1.55) 1.31 (1.26 to 1.37) 1.29 (1.24 to 1.35)
Obese class II (n=6026) 1.58 (1.48 to 1.69) 1.34 (1.26 to 1.44) 1.31 (1.22 to 1.41)
Obese class III
(n=2044)
1.55 (1.39 to 1.73) 1.36 (1.22 to 1.52) 1.38 (1.23 to 1.55)
Non-risk factors
Deprivation
quintiles**,¶
Least deprived
(n=32 780)
1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Q2 (n=25 022) 0.95 (0.91 to 1.00 0.97 (0.92 to 1.01) 0.96 (0.92 to 1.01)
Q3 (n=25 802) 0.93 (0.89 to 0.97) 0.95 (0.90 to 0.99) 0.94 (0.90 to 0.99)
Q4 (n=28 637) 0.92 (0.88 to 0.95) 0.90 (0.86 to 0.94) 0.89 (0.85 to 0.93)
Most deprived
(n=37 968)
0.85 (0.82 to 0.89) 0.85 (0.82 to 0.89) 0.83 (0.80 to 0.87)
Comorbidity†† Cardiovascular cluster
(n=53 120)
2.92 (2.87 to 3.03) 1.60 (1.55 to 1.65) 1.51 (1.46 to 1.56)
HTN (n=38 399) 2.83 (2.75 to 2.91) 1.53 (1.50 to 1.60) 1.49 (1.44 to 1.54)
CVD‡‡ (n=13 635) 2.50 (2.40 to 2.60) 1.19 (1.14 to 1.24) 1.07 (1.02 to 1.12)
DM (n=23 421) 1.97 (1.90 to 2.03) 1.22 (1.18 to 1.27) 1.16 (1.12 to 1.21)
CKD stage 3–5
(n=6098)
2.76 (2.61 to 2.91) 1.23 (1.16 to 1.31) 1.14 (1.06 to 1.21)
Stroke (n=3583) 2.20 (2.05 to 2.36) 1.03 (0.96 to 1.11) 0.98 (0.90 to 1.06)
Respiratory cluster
(n=16 616)
1.55 (1.28 to 1.40) 1.18 (1.13 to 1.22) 1.08 (1.03 to 1.13)
Asthma (n=12 792) 1.34 (1.28 to 1.40) 1.25 (1.19 to 1.31) 1.15 (1.10 to 1.21)
COPD (n=5206) 2.27 (2.14 to 2.41) 1.06 (1.00 to 1.13) 0.95 (0.89 to 1.02)
Mental health cluster
(n=4572)
1.18 (1.09 to 1.27) 0.94 (0.87 to 1.02) 0.91 (0.84 to 0.99)
Dementia (n=920) 2.52 (2.20 to 2.89) 0.92 (0.80 to 1.05) 0.82 (0.70 to 0.96)
Continued
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and 45–89 years, respectively.14 15 Additionally, Williams
et al15 reported higher PSA testing rates (7.1–8.9%) in
the southern UK general practices. Differences are likely
to be multifactorial including north and south social
deprivation differences.15 Based on reported 1 year PSA
testing rates in the UK, there has been a modest 2% rise
in testing rates from 6.2%14 15 to the current rate of
8.2% in our study.
We observed a signiﬁcant degree of variability in the
PSA testing rate between practices, which is similar to
previous ﬁndings, IQR 3.6–8.4% (Williams et al15), and
may be a reﬂection of differences in practice organisa-
tion, GP attitudes to testing or patient demographics.
Yearly PSA testing rates also vary greatly between devel-
oped countries with greater testing in some EU coun-
tries (Germany 35%),16 New Zealand (22%)18 and a
greater degree of testing in the USA (57%).19
Hjertholm et al13 found no difference in prostate cancer-
speciﬁc mortality between Danish practices with the
highest and lowest relative levels of PSA testing, but
there was a signiﬁcant increase in prostate cancer diag-
noses (mainly local disease), prostate biopsy and
prostatectomy.
PSA testing, level and age
Similar to the ﬁndings of others, PSA testing rates
increase with age,14–16 18–20 and peak testing prevalence
is among the patients aged 70–80 years old.14 15 18–20 A
third of those aged ≥70 years have PSA levels ≥4
ng/mL,14 15 21 which was consistent with our own ﬁndings.
PSA testing and ethnicity
In contrast to our study, Melia et al14 reported a decrease
in PSA testing with increasing proportions of black and
South Asian men. This ﬁnding was echoed by Gorday
et al22 who found a decreased rate of PSA testing among
black Canadian men. Further US studies have found
little difference in PSA uptake between black and white
patients.23–25 This is despite the increased incidence and
mortality of prostate cancer among black men.4 5 26 27
To the best of our knowledge, our study results are ﬁrst
to show higher rates of PSA testing among black men,
which marks a positive change in testing behaviour
potentially reﬂecting the increased underlying risk of
prostate cancer and possibly driven by increased aware-
ness of risk by patients and GPs. However, given that
black men are at up to three times greater risk of devel-
oping prostate cancer, the raised ORs for testing found
in our study do not sufﬁciently reﬂect the increased risk
of prostate cancer in this group. The decreased PSA
testing among Chinese men may reﬂect the reduced
incidence and mortality risk of prostate cancer in the
native Chinese population.28
PSA testing and social deprivation
The inverse relationship between socioeconomic status
and PSA testing observed in this study has been reported
in the UK14 15 and internationally.16 25 Purported reasons
for this relationship are reduced access to health services
in deprived areas and increased health awareness with
greater patient-driven testing among less deprived
patients.15 16 Prostate cancer mortality has also been
found to be higher in more deprived populations.27
Although we used internal quartiles of deprivation and
the studied London boroughs had high levels of depriv-
ation, PSA testing should still be a patient-driven and
clinician-driven process and efforts should to be made to
reduce any socioeconomic disparities in testing.
PSA testing and BMI
Similar to our study ﬁndings, US studies by Fontaine
et al29 and Fowke et al30 found a trend of increasing PSA
testing with increasing BMI. A raised BMI is a proposed
risk factor for prostate cancer, especially for advanced
Table 2 Continued
Cofactor Description
PSA study group (N=150 481)
Unadjusted
OR (95% CI)
Age-adjusted
OR (95% CI)*
Age-adjusted and
covariate-adjusted
OR (95% CI)†
SMI (n=3699) 0.92 (0.84 to 1.00) 0.95 (0.86 to 1.04) 0.95 (0.86 to 1.04)
Other cancer§§
(n=2719)
2.06 (1.90 to 2.24) 1.13 (1.03 to 1.23) 1.02 (0.93 to 1.12)
Bold typeface indicates significance at p<0.05.
*Age adjusted in age groups 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85–89, 90–94 and ≥95.
†Adjusted for age, BPH, prostatitis, tamsulosin or finasteride use.
‡Indian, Pakistani Bangladeshi or other Asian.
§11 462 BMI values missing.
¶272 Townsend scores missing.
**Quintiles based on Townsend Scores −5 to +10.
††Absence of comorbidity (individual or cluster) acts as reference group.
‡‡Includes IHD, PAD, AF and HF.
§§Excludes benign or malignant prostate cancer.
AF, atrial fibrillation; BPH, benign prostate hypertrophy; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD,
cardiovascular disease; DM, diabetes mellitus; HF, heart failure; HTN, hypertension; IHD, ischaemic heart disease; PSA, prostate-specific
antigen; SMI, significant mental illness.
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tumours.6 In this study, the increased PSA testing in
obese patients more likely represents opportunistic
testing in such patients who are more likely to have CVD
associated with increased healthcare access.30
PSA testing and comorbidity
Fowke et al30 found an increased rate of PSA testing in
patients with comorbidity, particularly CVD (HTN, DM
and high cholesterol) but no association with coronary
heart disease or respiratory disease. Minor dissimilarities
between the ﬁndings are likely to be the result of meth-
odological differences such as their inclusion of a
younger age range and adjustment for differing cofac-
tors (Fowke et al30).
A possible mechanism for the observed relationship
between some comorbidities and PSA testing is that
increased consultation rates and routine blood test mon-
itoring for comorbidity could increase the opportunity
to add PSA testing to existing monitoring tests. This
hypothesis was also suggested by Fowke et al30 who ﬁrst
reported for the positive association between CVD and
PSA testing among obese men. Lack of association
between PSA testing rates and other comorbidities may
be related to lack of routine blood test monitoring in
these comorbidities although this is unlikely to be the
sole explanation since increased PSA screening rates
were also seen in patients with asthma, a comorbidity
not associated with blood test monitoring.
Strengths and limitations
The results of this study are reﬂective of current clinical
practice as it features a large GP-registered population
with an inclusive criteria featuring a broad age range
with representation from various ethnicity groups, con-
ducted over a 5-year period. Our study used routinely
collected PSA testing data directly linked to compu-
terised general practice systems largely avoiding data
entry errors and reporting bias that occur with self-
reported data. The use of a retrospective study design
meant that PSA testing behaviour at the general practice
level was not altered by the knowledge of an ongoing
study.
Study limitations were that data on the PSA testing
intent and whether patients were symptomatic or asymp-
tomatic were not available. Similarly, we did not have
data on whether PSA testing was initiated by the patient
or GP. There are other drugs used on occasion for
patients with prostatic symptoms or that may inﬂuence
PSA levels that were not adjusted for in this study.
CONCLUSIONS
Based on our data from inner east London, 1-year PSA
testing prevalence showed a modest increase from previ-
ous studies but was relatively low compared to other EU
countries and the USA. Patients at higher risk of pros-
tate cancer (older patients, black men and obese
patients) had higher PSA testing rates; those at lower
risk (patients of Chinese ethnicity) had lower testing
rates. Independent of prostate cancer risk factors,
patients living in more socially deprived areas had lower
PSA testing rates and those with cardiovascular
comorbidities had higher testing rates likely due to
opportunistic testing. This study indicates that PSA
testing may be inﬂuenced by prostate cancer risk factors
and non-risk factors. In light of the current lack of evi-
dence demonstrating a beneﬁt in outcomes in testing
asymptomatic men, positive associations with non-
prostate risk factors may potentially increase the risk of
invasive diagnostic procedures. Future studies should
explore the intention for PSA testing in general practice,
especially in relation to ethnicity, comorbidity and social
deprivation.
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